Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Prelude Therapeutics Inc (PRLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 4 Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Exercised 9,375 restricted stock units @ $0
07/06/2023 4 Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Paid exercise price by delivering 3,242 shares @ $4.65, valued at $15.1k
Exercised 9,375 restricted stock units @ $0
05/26/2023 4 Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Bought 1,000 shares @ $5.0114, valued at $5k
Bought 900 shares @ $5.31, valued at $4.8k
05/25/2023 4 Lim Bryant David (Chief Legal Officer, Corp Sec.) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Bought 2,400 shares @ $5.39, valued at $12.9k
05/25/2023 4 Chardonnet Laurent (CFO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Bought 5,000 shares @ $5.5, valued at $27.5k
05/25/2023 4 Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Bought 11,856 shares @ $5.63, valued at $66.7k
05/24/2023 4 ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Bought 869,565 shares @ $5.75, valued at $5M
05/24/2023 4 Bonita David P (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Bought 869,565 shares @ $5.75, valued at $5M
05/24/2023 4 BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 121,178 options to buy @ $5.75, valued at $696.8k
Granted 1,327,044 options to buy @ $5.75, valued at $7.6M
Granted 970,220 options to buy @ $0.0001, valued at $97
Granted 10,625,036 options to buy @ $0.0001, valued at $1.1k
03/02/2023 4 Lim Bryant David (Chief Legal Officer, Corp Sec.) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 250,000 options to buy @ $5.93, valued at $1.5M
02/09/2023 4 Scherle Peggy (Chief Scientific Officer) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 135,000 options to buy @ $7.2, valued at $972k
02/09/2023 4 Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 135,000 options to buy @ $7.2, valued at $972k
02/09/2023 4 Chardonnet Laurent (CFO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 135,000 options to buy @ $7.2, valued at $972k
02/09/2023 4 Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 150,000 options to buy @ $7.2, valued at $1.1M
02/09/2023 4 Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 330,000 options to buy @ $7.2, valued at $2.4M
12/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/12/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/04/2022 4 Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 460,000 options to buy @ $4.86, valued at $2.2M
Granted 150,000 restricted stock units @ $0
04/04/2022 4 Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Exercised 36,062 shares @ $1.89, valued at $68.2k
Exercised 36,062 options to buy @ $1.89, valued at $68.2k
03/22/2022 4 Chardonnet Laurent (CFO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 6,500 shares @ $7.51, valued at $48.8k
02/17/2022 4 Scherle Peggy (Chief Scientific Officer) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 100,000 options to buy @ $10.58, valued at $1.1M
02/17/2022 4 Chardonnet Laurent (CFO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 90,000 options to buy @ $10.58, valued at $952.2k
02/17/2022 4 Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 327,900 options to buy @ $10.58, valued at $3.5M
02/17/2022 4 Morosini Deborah (EVP, Chief of Clinical Affairs) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 90,000 options to buy @ $10.58, valued at $952.2k
02/17/2022 4 Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 100,000 options to buy @ $10.58, valued at $1.1M
01/05/2022 4 Sandor Victor (Director) has filed a Form 4 on Prelude Therapeutics Inc
Txns: Granted 11,206 options to buy @ $13.22, valued at $148.1k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy